6 active not recruiting. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 6 |
Follow Ischemic Stroke: new trials by email Literature Review of Ischemic Stroke trials Research Report on Ischemic Stroke
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2 Tocilizumab, Placebo - Acute Ischemic Stroke | Phase 3 | Active not recruiting | Capital Medical University | 692 | 2025-12-05 | 2026-10-06 |
| Regular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis Regular physical exercise, Control group - Ischemic Stroke, Transient Ischemic Attack | Phase 3 | Active not recruiting | Capital Medical University | 1300 | 2024-10-10 | 2025-11-25 |
| Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke Methylprednisolone sodium succinate, Placebo - Acute Ischemic Stroke, Large Infarct Core | Phase 3 | Active not recruiting | Wan-Jin Chen | 928 | 2024-08-01 | 2025-12-03 |
| A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE Milvexian, Placebo - Ischemic Stroke; Ischemic Attack, Transient | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 12523 | 2023-02-15 | 2026-09-25 |
| Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia Flecainide - Patent Foramen Ovale, Atrial Arrhythmia | Phase 3 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 186 | 2022-03-23 | 2026-09-09 |
| Enhancement of Stroke Rehabilitation With Levodopa IMP Levodopa 100mg/Carbidopa 25mg, Matching placebo - Acute Stroke, Stroke Rehabilitation | Phase 3 | Active not recruiting | University Hospital, Basel, Switzerland | 610 | 2019-06-14 | 2024-10-15 |
Stroke (2) · Atrial Fibrillation (1) · Foramen Ovale, Patent (1) · Ischemic Attack, Transient (1)
Brain Diseases (6) · Cardiovascular Diseases (6) · Central Nervous System Diseases (6) · Cerebrovascular Disorders (6) · Nervous System Diseases (6) · Vascular Diseases (6) · Stroke (4) · Arrhythmias, Cardiac (1) · Brain Ischemia (1) · Cardiovascular Abnormalities (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Heart Defects, Congenital (1) · Heart Diseases (1) · Heart Septal Defects (1)
Carbidopa (1) · Control Groups (1) · Flecainide (1) · Methylprednisolone Hemisuccinate (1) · milvexian (1) · tocilizumab (1)
Capital Medical University (2) · Assistance Publique - Hôpitaux de Paris (1) · Janssen Research & Development, LLC (1) · University Hospital, Basel, Switzerland (1) · Wan-Jin Chen (1)
China (4) · France (2) · Switzerland (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Croatia (1) · Czechia (1) · Denmark (1) · Estonia (1)
PMID 38216511, PMID 39222035, PMID 40982270, PMID 41701756, PMID 41791675, PMID 42052962, PMID 42525438
2018 (1)